Scotia Capital’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.31M Buy
31,792
+2,618
+9% +$860K 0.04% 222
2025
Q4
$10.2M Buy
29,174
+868
+3% +$293K 0.04% 208
2025
Q3
$9.15M Buy
28,306
+5,494
+24% +$1.71M 0.04% 212
2025
Q2
$8.87M Buy
22,812
+1,202
+6% +$483K 0.04% 207
2025
Q1
$9.4M Sell
21,610
-2,881
-12% -$1.16M 0.05% 193
2024
Q4
$9.04M Buy
24,491
+3,583
+17% +$1.5M 0.05% 188
2024
Q3
$10.9M Buy
20,908
+796
+4% +$425K 0.06% 168
2024
Q2
$10.9M Buy
20,112
+1,635
+9% +$864K 0.06% 161
2024
Q1
$9.58M Buy
18,477
+2,790
+18% +$1.39M 0.06% 171
2023
Q4
$7.4M Buy
15,687
+940
+6% +$435K 0.05% 190
2023
Q3
$6.42M Buy
14,747
+3,720
+34% +$1.69M 0.05% 198
2023
Q2
$4.9M Buy
11,027
+4,817
+78% +$2.22M 0.03% 229
2023
Q1
$2.86M Buy
6,210
+100
+2% +$47.6K 0.02% 301
2022
Q4
$3.13M Sell
6,110
-442
-7% -$224K 0.02% 288
2022
Q3
$2.98M Sell
6,552
-516
-7% -$247K 0.02% 282
2022
Q2
$3.41M Sell
7,068
-8,047
-53% -$3.98M 0.03% 278
2022
Q1
$7.42M Sell
15,115
-69
-0.5% -$31.5K 0.05% 198
2021
Q4
$7.04M Sell
15,184
-447
-3% -$188K 0.05% 206
2021
Q3
$5.83M Buy
15,631
+827
+6% +$314K 0.04% 225
2021
Q2
$5.65M Sell
14,804
-3,506
-19% -$1.34M 0.04% 234
2021
Q1
$6.57M Buy
18,310
+116
+0.6% +$37.3K 0.05% 198
2020
Q4
$5.84M Buy
18,194
+1,012
+6% +$311K 0.05% 188
2020
Q3
$4.62M Buy
+17,182
New +$4.62M 0.05% 197
2020
Q2
Sell
-15,567
Closed -$3.53M 674
2020
Q1
$3.53M Buy
15,567
+529
+4% +$144K 0.05% 188
2019
Q4
$4.54M Sell
15,038
-413
-3% -$114K 0.05% 184
2019
Q3
$3.71M Sell
15,451
-408
-3% -$112K 0.04% 204
2019
Q2
$4.48M Buy
15,859
+7,061
+80% +$1.93M 0.05% 181
2019
Q1
$2.52M Buy
8,798
+450
+5% +$130K 0.03% 246
2018
Q4
$2.19M Sell
8,348
-190
-2% -$52.2K 0.03% 254
2018
Q3
$2.34M Buy
8,538
+48
+0.6% +$12.5K 0.03% 270
2018
Q2
$1.85M Buy
8,490
+216
+3% +$50K 0.03% 294
2018
Q1
$1.82M Buy
8,274
+1,704
+26% +$400K 0.03% 302
2017
Q4
$1.48M Buy
6,570
+64
+1% +$13.6K 0.02% 347
2017
Q3
$1.24M Buy
6,506
+62
+1% +$11.8K 0.02% 351
2017
Q2
$1.21M Sell
6,444
-177
-3% -$31.8K 0.02% 330
2017
Q1
$1.1M Sell
6,621
-2,524
-28% -$402K 0.02% 361
2016
Q4
$1.31M Buy
9,145
+124
+1% +$16.6K 0.02% 370
2016
Q3
$1.13M Buy
9,021
+855
+10% +$110K 0.02% 394
2016
Q2
$1.07M Buy
8,166
+1,104
+16% +$151K 0.02% 370
2016
Q1
$982K Sell
7,062
-835
-11% -$112K 0.02% 361
2015
Q4
$1.09M Hold
7,897
0.02% 396
2015
Q3
$1.1M Sell
7,897
-804
-9% -$121K 0.03% 369
2015
Q2
$1.42M Buy
8,701
+3,071
+55% +$491K 0.03% 331
2015
Q1
$870K Buy
+5,630
New +$802K 0.02% 332
2014
Q4
Sell
-5,701
Closed -$681K 590
2014
Q3
$681K Sell
5,701
-5
-0.1% -$573 0.01% 369
2014
Q2
$614K Buy
5,706
+219
+4% +$22.6K 0.01% 372
2014
Q1
$546K Buy
+5,487
New +$496K 0.01% 388
2013
Q3
Sell
-24,150
Closed -$1.98M 495
2013
Q2
$1.98M Buy
+24,150
New +$1.81M 0.08% 164

Other funds holding ELV

Scotia Capital's ELV Position: Q1 2026 in Review

Scotia Capital increased its Elevance Health (ELV) stake by 9% in Q1 2026, buying an estimated $860K and bringing the position to 31,792 shares worth $9.31M. The position accounts for 0.04% of the portfolio, ranked #222.

Scotia Capital first reported a position in ELV in Q2 2013 and has held it in 48 quarters since. The position peaked at $10.9M in Q2 2024. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.

  • Scotia Capital held 31,792 shares of Elevance Health worth $9.31M as of Q1 2026.
  • Scotia Capital bought 2,618 Elevance Health shares in Q1 2026, an estimated $860K.
  • Elevance Health made up 0.04% of Scotia Capital's portfolio in Q1 2026, its #222 holding.
  • Scotia Capital first reported a position in Elevance Health in Q2 2013 and has held it in 48 quarters since.
  • Scotia Capital's Elevance Health position peaked at $10.9M in Q2 2024.
  • 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.

Based on Scotia Capital's 13F filing for Q1 2026, filed 13 May 2026.